Fischer Imaging will remain listed on the Nasdaq exchange at least until Nov. 14, at which time the company must have filed necessary documentation or face delisting. In order to remain on the exchange, Fischer must complete an amended Form 10-Q for the
Fischer Imaging will remain listed on the Nasdaq exchange at least until Nov. 14, at which time the company must have filed necessary documentation or face delisting. In order to remain on the exchange, Fischer must complete an amended Form 10-Q for the quarter ended June 30, 2002, including an affirmative disclosure that the report has been reviewed consistent with SAS 71, as well as a Form 10-Q for the quarter ended Sept. 30, 2002. Alliance Pharmaceutical had no such recourse. The company announced Oct. 17 its delisting from the exchange for failure to meet certain requirements. The company¹s stock is now being traded on Nasdaq's over-the-counter bulletin board.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.